Lysophosphatidylcholine stimulates EGF receptor activation and mesangial cell proliferation: Regulatory role of Src and PKC

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1771, Issue 11, 2007, Pages 1364-1371

  Bassa, Babu V ^a,b   Noh, Jung W ^a,b   Ganji, Shobha H ^a,b   Shin, Mi Kyung ^a,b   Roh, Daeyoung D ^a,b   Kamanna, Vaijinath S ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

EGF receptor; Glomerular disease; Low density lipoprotein; Lysophosphatidylcholine; Mesangial cell proliferation; Signal transduction

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; BISINDOLYLMALEIMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LYSOPHOSPHATIDYLCHOLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; GLOMERULOPATHY; HUMAN; HUMAN CELL; LIPOPROTEIN BLOOD LEVEL; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TRANSACTIVATION; VASCULAR DISEASE;

CELL PROLIFERATION; CELLS, CULTURED; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; INDOLES; LYSOPHOSPHATIDYLCHOLINES; MALEIMIDES; MAP KINASE SIGNALING SYSTEM; MESANGIAL CELLS; PROTEIN KINASE C; RECEPTOR, EPIDERMAL GROWTH FACTOR; SRC-FAMILY KINASES; TYRPHOSTINS;

EID: 36749009656     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2007.09.004     Document Type: Article

References (56)

1. Joles J.A., Willekes-Koolschijn N., Scheek L.M., Koomans H.A., Rabelink T.J., and Van Jol A. Lipoprotein phospholipid composition and LCAT activity in nephrotic and analbuminic rats. Kidney Int. 46 (1994) 97-104
2. Sekas G., Patton G.M., Lincoln E.C., and Robins S.J. Origin of plasma lysophosphatidylcholine: evidence for direct hepatic secretion in the rat. J. Lab. Clin. Med. 105 (1985) 190-194
3. Kohno M., Yokokawa K., Yasunari K., Minami M., Kano H., Hanechira T., and Yoshikawa J. Induction of lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation 98 (1998) 353-359
4. Parthasarathy S., and Barnett J. Phosholipase A2 activity of low-density lipoproteins: evidence for an intrinsic phospholipase A2 activity of apoprotein B-100. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 9741-9745
5. Steinbrecher U.P., Parthasarathy S., Leake D.S., Witzum J.L., and Seinberg D. Modification of low-density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low-density lipoprotein phospholipids. Proc. Natl. Acad. Sci. U. S. A. 81 (1984) 3883-3887
6. Watanabe T., Pakala R., Koba S., Katagiri T., and Benedict C.R. Lysophosphatidylcholine and reactive oxygen species mediate the synergistic effect of mildly oxidized LDL with serotonin on vascular smooth muscle cell proliferation. Circulation 103 (2001) 1440-1445
7. Kume N., Cybulsky M.I., and Gimbrone Jr. M.A. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 90 (1992) 1138-1144
8. Chai Y.C., Howe P.H., DiCorleto P.E., and Chislom G.M. Oxidized low-density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells: evidence for release of FGF-2. J. Biol. Chem. 271 (1996) 17791-17797
9. Quinn M.T., Parthasarathy S., and Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 2805-2809
10. Kugiyama K., Kerns S.A., Morrisett J.D., Roberts R., and Henry P.D. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344 (1990) 160-162
11. Kume N., and Gimbrone Jr. M.A. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human vascular endothelial cells. J. Clin. Invest. 93 (1994) 907-911
12. Nakano T., Raines E.W., Abraham J.A., Klagsburn M., and Ross R. Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 1069-1073
13. Stremler K.E., Stafforini D.M., Prescott S.M., Zimmerman G.A., and McIntyre T.M. An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. J. Biol. Chem. 264 (1989) 5331-5334
14. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320 (1989) 915-924
15. Steinberg D., and Witztum J.L. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?. Circulation 105 (2002) 2107-2711
16. Kamanna V.S., Bassa B.V., and Kirschenbaum M.A. Atherogenic lipoproteins and human disease: extending concepts beyond the heart to the kidney. Curr. Opin. Nephrol. Hypertens. 6 (1997) 205-211
17. Keane W.F., Kasiske B.L., and O'Donnell M.P. Lipids and progressive glomerulosclerosis. Am. J. Nephrol. 8 (1988) 261-271
18. Diamond J.R. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int. 39 (1991) S29-S34
19. Fornasieri A., Perugini C., Seccia M., Napodano P., and D'Amico G. Circulating antibodies recognizing oxidatively-modified low-density lipoproteins in patients with IgA nephropathy, membranous glomerulonephritis and focal glomerulosclerosis. J. Nephrol. 15 (2002) 349-357
20. Tits L.V., Graaf J.D., Hak-Lemmers H., Brdie S., Demacker P., Holvoet P., and Stalenhoef A. Increased levels of low-density lipoprotein oxidation in patients with familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis. Lab. Invest. 83 (2003) 13-21
21. Maggi E., Bellazzi R., Falaschi F., Frattoni A., Perani G., Finardi G., Gazo A., Nai M., Romanini D., and Bellomo G. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis?. Kidney Int. 45 (1994) 876-883
22. Maggi E., Bellazzi R., Gazo A., Seccia M., and Bellomo G. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int. 46 (1994) 869-876
23. Holvoet P., Donck J., Landeloos M., Brouwers E., Luijtens K., Arnout J., Lesaffre E., Vanrenterghem Y., and Collen D. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb. Haemost. 76 (1996) 663-669
24. Itabe H., Yamamoto H., Imanaka T., Shimamura K., Uchiyama H., Kimura J., Sanaka T., Hata Y., and Takano T. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J. Lipid Res. 37 (1996) 45-53
25. Shoji T., Fukumoto M., Kimoto E., Shinohara K., Emoto M., Tahara H., Koyama H., Ishimura E., Nakatani T., Miki T., Tsujimoto Y., Tabata T., and Nishizawa Y. Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. Kidney Int. 62 (2002) 2230-2237
26. Lee H.S., and Kim Y.S. Identification of oxidized low-density lipoprotein in human renal biopsies. Kidney Int. 54 (1998) 848-856
27. Sasagawa T., Suzuki K., Shiota T., Kondo T., and Okita M. The significance of plasma lysophospholipids in patients with renal failure on hemodialysis. J. Nutr. Sci. Vitaminol. (Tokyo) 44 (1998) 809-818
28. Vuong T.D., Stroes E.S., Willekes-Koolschijin N., Rabelink T.J., Koomans H.A., and Joles J.A. Hypoalbuminemia increases lysophosphatidylcholine in low-density lipoprotein of normocholesterolemic subjects. Kidney Int. 55 (1999) 1005-1010
29. Kamanna V.S., Pai R., Roh D.D., and Kirschenbaum M.A. Oxidative modification of low-density lipoprotein enhances murine mesangial cell cytokines associated with monocyte migration, differentiation, and proliferation. Lab. Invest. 74 (1996) 1067-1079
30. Kamanna V.S., Pai R., Ha H., Kirschenbaum M.A., and Roh D.D. Oxidized low-density lipoprotein stimulates monocyte adhesion to endothelial cells. Kidney Int. 55 (1999) 2192-2202
31. Roh D.D., Kamanna V.S., and Kirschenbaum M.A. Oxidative modification of low density lipoprotein enhances mesangial cell protein synthesis and gene expression of extracellular matrix proteins. Am. J. Nephrol. 18 (1998) 344-350
32. Roh D.D., Kamanna V.S., and Kirschenbaum M.A. Atherogenic lipoproteins enhance murine cortical epithelial cell fibronectin protein synthesis and gene expression. Am. J. Nephrol. 18 (1998) 83-88
33. Tone Y., Yukawa S., Varghese Z., and Moorehead J.F. Lysophosphatidylcholine induces platelet-derived growth factor gene expression in a human mesangial cell line. Kidney Int. 71 (1999) S182-S185
34. Bassa B.V., Roh D.D., Vaziri N.D., Kirschenbaum M.A., and Kamanna V.S. Lysophosphatidylcholine activates mesangial cell PKC and MAP kinase by PLCγ-1 and tyrosine kinase-Ras pathways. Am. J. Physiol. 277 (1999) F328-F337
35. Hackel P.O., Zwick E., Prenzel N., and Ulrich A. Epidermal growth factor receptor: critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol. 11 (1999) 184-189
36. Moghal N., and Sternberg P.W. Multiple positive and negative regulators of signaling by the EGF-receptor. Curr. Opin. Cell Biol. 11 (1999) 190-1996
37. Gould K.L., and Hunter T. Platelet-derived growth factor induces multisite phosphorylation of pp60 c-Src and increases its protein tyrosine kinase activity. Mol. Cell. Biol. 8 (1988) 3345-3356
38. 2+ in A431 carcinoma cells. J. Biol. Chem. 273 (1998) 3121-3124
39. Toullec D., Pianetti P., Coste H., Bellevergue P., Grand-Perret T., Ajakane M., Baudet V., Boissin P., Boursier E., and Loriolle F. The bisindolylmaleimide GF 109203X is a potent, and selective inhibitor of protein kinase C. J. Biol. Chem. 266 (1991) 15771-15781
40. Kamanna V.S., Pai R., Bassa B., and Kirschenbaum M.A. Activation of mesangial cells with TNF-α stimulates M-CSF gene expression and monocyte proliferation: evidence for involvement of protein kinase C and protein tyrosine kinase. Biochim. Biophys. Acta 1313 (1996) 161-172
41. Rikitake Y., Kawashima S., Takahashi T., Ueyama T., Ishido S., Inoue N., Hirata K., and Yokoyyama M. Regulation of tyrosine phosphorylation of PYK2 in vascular endothelial cells by lysophosphatidylcholine. Am. J. Physiol. 28 (2001) H266-H274
42. Legardi A., Chitu V., Szukacsov V., Fajka-Boja R., Szekely S.K., and Monostori E. Lysophosphatidylcohline is a regulator of tyrosine kinase activity and intracellular Ca(2+) level in jurkat T cell line. Immunol. Lett. 30 (2004) 17-21
43. Yamakawa T., Tanaka S., Yamakawa Y., Kamei J., Numaguchi K., Motley E.D., Inagami T., and Eguchi S. Lysophosphatidylcholine activates extracellular signal-regulated kinases1/2 through reactive oxygen species in rat vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 752-758
44. Takahashi M., Okazaki H., Ogata Y., Takeuchi K., Ikeda U., and Shimada K. Lysophosphatidylcholione induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis 161 (2002) 387-394
45. Fang X., Gibson S., Flowers M., Furui T., Bast Jr. R.C., and Mills G.D. Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity. J. Biol. Chem. 272 (1997) 13683-13689
46. Kugiyama K., Ohgushi M., Sugiyama S., Murohara T., Fukunaga K., Miyamoto E., and Yasue H. Lysophosphatidylcholine inhibits surface receptor-mediated intracellular signals in endothelial cells by a pathway involving protein kinase C activation. Circ. Res. 71 (1992) 1422-1428
47. Ohgushi M., Kugiyama K., Fukunaga K., Murohara T., Sugiyama S., Miyamoto E., and Yasue H. Protein kinase C inhibitors prevent impairment of endothelium-dependent relaxation by oxidatively modified LDL. Arterioscler. Thromb 13 (1993) 1525-1532
48. Sugiyama S., Kugiyama K., Ohgushi M., Fujimoto K., and Hirofumi Y. Lysophosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries. Circ. Res. 74 (1994) 565-575
49. Daub H., Weiss F.U., Wallasch C., and Ullrich A. Role of transactivation of the EGF receptor in signaling by G protein-coupled receptors. Nature 379 (1996) 557-560
50. Grewal J.S., Luttrell L.M., and Raymond J.R. G protein-coupled receptors desensitize and downregulate epidermal growth factor receptors in renal mesangial cells. J. Biol. Chem. 276 (2001) 27335-27344
51. Northwood I.C., and Davis R.J. Activation of the epidermal growth factor receptor tyrosine protein kinase in the absence of receptor oligomerization. J. Biol. Chem. 263 (1988) 7450-7453
52. Bremer E.G., Schlessinger J., and Hakomori S. Ganglioside-mediated modulation of cell growth. Effects of GM3 on tyrosine phosphorylation of the epidermal growth factor receptor. J. Biol. Chem. 261 (1986) 2434-2440
53. Tsai W., Morielli A.D., and Peralta E.G. The m1 muscarinic acetylcholine receptor transactivates the EGF receptor to modulate ion channel activity. EMBO J. 16 (1997) 4597-4605
54. Morrison P., Takishima K., and Rosner M.R. Role of threonine residues in the epidermal growth factor receptor by protein kinase C and mitogen-activated protein kinase. J. Biol. Chem. 268 (1993) 15536-15543
55. Kamanna V.S., Bassa B.V., Vaziri N.D., and Roh D.D. Atherogenic lipoproteins and tyrosine kinase mitogenic signaling in mesangial cells. Kidney Int. 56 (1999) S70-S75
56. Qiao J., Huang F., Naikawadi R.P., Kim K.S., Said T., and Lum H. Lysophosphatidylcholine impairs endothelial barrier function through the G protein-coupled receptor GPR4. Am. J. Physiol. 291 (2006) L91-L101